Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study.
delayed oophorectomy
early menopause
high risk of breast and ovarian cancer
ovarian cancer prevention
radical fimbriectomy
risk-reducing surgery
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 02 2023
10 02 2023
Historique:
received:
20
01
2023
revised:
07
02
2023
accepted:
07
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Risk-reducing salpingo-oophorectomy is the gold standard for the prophylaxis of ovarian cancer in high-risk women. Due to significant adverse effects, 20-30% of women delay or refuse early oophorectomy. This prospective pilot study (NCT01608074) aimed to assess the efficacy of radical fimbriectomy followed by a delayed oophorectomy in preventing ovarian and pelvic invasive cancer (the primary endpoint) and to evaluate the safety of both procedures. The key eligibility criteria were pre-menopausal women ≥35 years with a high risk of ovarian cancer who refused a risk-reducing salpingo-oophorectomy. All the surgical specimens were subjected to the SEE-FIM protocol. From January 2012 to October 2014, 121 patients underwent RF, with 51 in an ambulatory setting. Occult neoplasia was found in two cases, with one tubal high-grade serous ovarian carcinoma. Two patients experienced grade 1 intraoperative complications. No early or delayed grade ≥3 post-operative complications occurred. After 7.3 years of median follow-up, no cases of pelvic invasive cancer have been noted. Three of the fifty-two patients developed de novo breast cancer. One BRCA1-mutated woman delivered twins safely. Twenty-five patients underwent menopause, including fifteen who had received chemotherapy for breast cancer, and twenty-three underwent menopause before the delayed oophorectomy, while two did not undergo a delayed oophorectomy at all. Overall, 46 women underwent a delayed oophorectomy. No abnormalities were found in any delayed oophorectomy specimens. Radical fimbriectomy followed by delayed oophorectomy appears to be a safe and well-tolerated risk-reducing approach, which avoids early menopause for patients with a high risk of breast and ovarian cancer.
Identifiants
pubmed: 36831483
pii: cancers15041141
doi: 10.3390/cancers15041141
pmc: PMC9954021
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : French National Cancer Institute
ID : PHRC 2011-06
Références
JAMA. 2011 Jun 8;305(22):2295-303
pubmed: 21642681
Int J Gynecol Pathol. 2011 Jan;30(1):12-21
pubmed: 21131839
Am J Obstet Gynecol. 2011 Jan;204(1):19.e1-6
pubmed: 20619389
Clin Cancer Res. 2017 Jul 15;23(14):3628-3637
pubmed: 28143870
J Clin Oncol. 2007 Apr 10;25(11):1329-33
pubmed: 17416853
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Nat Rev Cancer. 2010 Nov;10(11):803-8
pubmed: 20944665
Int J Gynecol Pathol. 2011 Jan;30(1):4-11
pubmed: 21131840
Am J Surg Pathol. 2011 Dec;35(12):1766-75
pubmed: 21989347
Maturitas. 2011 Nov;70(3):261-5
pubmed: 21893388
J Natl Cancer Inst. 2015 Aug 27;107(11):
pubmed: 26315354
Lancet. 2021 Jun 5;397(10290):2182-2193
pubmed: 33991479
Hum Reprod. 2011 Dec;26(12):3494-5; author reply 3495
pubmed: 22016419
Am J Surg Pathol. 2007 Feb;31(2):161-9
pubmed: 17255760
J Pathol. 2001 Nov;195(4):451-6
pubmed: 11745677
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Pathol Transl Med. 2018 Jan;52(1):21-27
pubmed: 27539290
Hum Mutat. 2012 Apr;33(4):690-702
pubmed: 22253144
Cochrane Database Syst Rev. 2018 Aug 24;8:CD012464
pubmed: 30141832
Br J Cancer. 2019 Jul;121(1):15-21
pubmed: 30971774
Ann Oncol. 2013 Dec;24 Suppl 10:x16-21
pubmed: 24265397
Int J Gynecol Pathol. 2015 Mar;34(2):112-20
pubmed: 25675178
Breast Cancer Res Treat. 2019 Oct;177(3):723-733
pubmed: 31302855
BJOG. 2017 May;124(6):872-878
pubmed: 28218502
Obstet Gynecol Sci. 2019 Nov;62(6):382-390
pubmed: 31777733
JAMA Oncol. 2021 Aug 01;7(8):1203-1212
pubmed: 34081085
Nat Commun. 2019 Nov 26;10(1):5367
pubmed: 31772167
J Clin Endocrinol Metab. 2017 Oct 1;102(10):3839-3847
pubmed: 28938488
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Int J Gynecol Cancer. 2021 Feb;31(2):286-291
pubmed: 32907814
Cancers (Basel). 2018 Nov 28;10(12):
pubmed: 30486509
J Minim Invasive Gynecol. 2017 Jul - Aug;24(5):837-842
pubmed: 28479170
J Cancer Res Ther. 2018 Apr-Jun;14(3):543-548
pubmed: 29893313
Maturitas. 2010 Jul;66(3):310-4
pubmed: 20409655
Cancer Cell. 2013 Dec 9;24(6):751-65
pubmed: 24332043
Curr Oncol. 2017 Dec;24(6):e494-e502
pubmed: 29270058
Gynecol Oncol. 2017 Jun;145(3):595-602
pubmed: 28237618
Med Decis Making. 2009 May-Jun;29(3):343-50
pubmed: 19073996
Obstet Gynecol. 2009 May;113(5):1027-1037
pubmed: 19384117
Cancers (Basel). 2018 Nov 12;10(11):
pubmed: 30424539
JNCI Cancer Spectr. 2018 Dec 14;2(4):pky061
pubmed: 31360879
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47
pubmed: 22144499
Adv Anat Pathol. 2006 Jan;13(1):1-7
pubmed: 16462151
Gynecol Oncol. 2009 Jun;113(3):391-6
pubmed: 19237187
Gynecol Oncol. 2011 Jun 1;121(3):472-6
pubmed: 21411127
Gynecol Oncol. 2019 Jan;152(1):145-150
pubmed: 30414741